Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation
Ital J Dermatol Venerol
.
2024 Feb;159(1):64-65.
doi: 10.23736/S2784-8671.23.07648-X.
Epub 2023 Nov 23.
Authors
Flavia Manzo Margiotta
1
,
Alessandra Michelucci
1
,
Eugenio Capalbo
2
,
Federica Ricceri
3
,
Elia Rosi
4
,
Susanna Rossari
5
,
Michela Magnano
5
,
Imma Savarese
6
,
Nicola Milanesi
6
,
Barbara Simoni
7
,
Marco Romanelli
1
,
Pietro Rubegni
2
,
Antonella DI Cesare
4
,
Salvatore Panduri
1
,
Leonardo Pescitelli
8
,
Emanuele Trovato
9
,
Francesca Prignano
4
Affiliations
1
Department of Dermatology, University of Pisa, Pisa, Italy.
2
Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy.
3
Unit of Dermatology, San Donato Hospital, Arezzo, Italy.
4
Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
5
Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy.
6
Department of Dermatology, San Jacopo Hospital, Pistoia, Italy.
7
Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy.
8
Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy.
9
Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy -
[email protected]
.
PMID:
37997317
DOI:
10.23736/S2784-8671.23.07648-X
No abstract available
Publication types
Multicenter Study
MeSH terms
Antibodies, Monoclonal / therapeutic use
Humans
Immunoglobulin Class Switching*
Psoriasis* / drug therapy
Retrospective Studies
Substances
risankizumab
Antibodies, Monoclonal